The RESCUE trial included subjects with moderate-to-severe chronic kidney disease and hsCRP of >2 mg/L, administered with either placebo or ziltivekimab, a novel IL-6 monoclonal antibody, over a period of 2 years. This evidence concerns the gene IL6 and chronic kidney disease.